Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Jacquie Lee
Drug companies can’t avoid including kids in certain clinical studies now that the FDA has finally closed a loophole within a pediatric research law.
The Food and Drug Administration has been emphasizing the need for kids to be included in drug trials since Scott Gottlieb took over as commissioner of the agency in May 2017. The Pediatric Research Equity Act (PREA), passed in 2003, requires drug companies to study some products in children. Drug companies have been skirting the requirement using certain exemptions. The biggest exemption revolves around so-called orphan drugs that treat small patient populations and rare diseases.
The agency gives special incentives to manufacturers—like tax credits and seven extra years of marketing exclusivity—for producing drugs that treat diseases affecting 200,000 or fewer people in the U.S. Drugmakers that create an orphan drug don’t need to conduct research for that drug on pediatric populations. Consequently, drug companies have been designating more and more drugs as orphan drugs in order to skirt the pediatric research responsibility.
The FDA will now be cracking down on what it considers an orphan drug. The agency “does not expect to grant any additional orphan drug designation to drugs for pediatric subpopulations of common diseases,” as it had in the past.
This latest industry advice, a notice for which is set to be published in the Federal Register July 27, closes that loophole. It also helps fulfill the agency’s goal of beefing up research on treatment for children.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)